Michele Schiavon

Dr. Michele Schiavon

University of Padova - Department of Information Engineering
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2017 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Closed access
Michele SchiavonMichele Schiavon
Michele Schiavon
Chiara Dalla ManChiara Dalla Man
Chiara Dalla Man
CCClaudio Cobelli
Claudio Cobelli
Objective: Subcutaneous (sc) administration of fast-acting insulin analogues is key in conventional therapy of type 1 diabetes (T1D). A model of sc insulin absorption would be helpful for optimizing insulin therapy and test new open- and closed-loop treatment strategies in in silico platforms. Some models have been published in literature, but none was assessed on a frequently-sampled large dataset of T1D subjects. The aim here is to propose a model of sc absorption of fast-acting insulin able to describe the data and precisely estimate model parameters with a clear physiological interpretation. Methods: Three candidate models were identified on 116 T1D subjects who underwent a single sc injection of fast-acting insulin and were compared on the basis of their ability to describe the data and numerical identifiability. Results: A linear two-compartment model including a subject-specific delay in sc insulin absorption is proposed. On average, a delay of 7.6 min in insulin appearance in the first compartment is detected, then insulin is slowly absorbed into plasma (in 23% of the subjects) with a rate of $0.0034 \rm{min}^{-1}$, while the remaining diffuses into the second compartment, with a rate constant of $0.028 \rm{min}^{-1}$, and then finally absorbed into plasma with a rate constant of $0.0014 \rm{min}^{-1}$. Conclusion: Among the three tested models, the one proposed here is the only one able to both accurately describe plasma insulin data after a single sc injection and precisely estimate physiologically plausible parameters. The model needs to be further tested in case of variable sc insulin delivery and/or multiple insulin doses. Significance: Results are expected to help the development of new open- and closed-loop insulin treatment strategies.

6 April 2021 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
Michele SchiavonMichele Schiavon
Michele Schiavon
Roberto VisentinRoberto Visentin
Roberto Visentin
BGBritta Göbel
Britta Göbel
MRMichela Riz
Michela Riz
CCClaudio Cobelli
Claudio Cobelli
Chiara Dalla ManChiara Dalla Man
Chiara Dalla Man
Objective Dual glucagon‐like peptide‐1/glucagon receptor agonist (GLP‐1/GCG RA) SAR425899 showed positive effects on glycemic control and reduction of body weight in overweight to obese patients with type 2 diabetes mellitus (T2D) after 4 weeks of treatment, with a safety profile comparable with GLP‐1 RA. Here, we aim to give further insights into SAR425899 efficacy, by also providing direct comparison against the GLP‐1 RA Liraglutide in terms of key parameters of glucose metabolism. Research Design and Methods Seventy overweight to obese subjects with T2D were randomized to receive once‐daily subcutaneous administrations of SAR425899 (0.12 mg, 0.16 mg or 0.20 mg), Liraglutide (1.80 mg) or placebo for 26 weeks. Mixed meal tolerance tests (MMTT) were conducted at baseline (BSL) and at the end of treatment (EOT). Metabolic indices of insulin action and secretion were assessed via Homeostasis Model Assessment (HOMA2) and oral minimal model (OMM) methods. Results From BSL to EOT (Median [25th,75th]percentile), HOMA2 quantified a significant improvement in basal insulin action in Liraglutide (35 [21,74]%), while secretion enhanced both in SAR42899 (125 [63,228]%) and Liraglutide (73 [43,147]%). OMM quantified, both in SAR425899 and Liraglutide, a significant improvement in insulin sensitivity (203 [58,440]% and 36 [21,197]%), basal β‐cell responsiveness (67 [34,112]% and 40 [16,59]%), above‐basal β‐cell responsiveness (139 [64,261]% and 69 [‐15,120]%). A significant delay in glucose absorption was highlighted in SAR425899 (37 [52,18]%). Conclusions SAR425899 and Liraglutide improved postprandial glucose control in overweight to obese subjects with T2D. A significantly higher enhancement in β‐cell function was shown by SAR425899 than Liraglutide.

1 July 2021 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
DRDavide Romeres
Davide Romeres
Michele SchiavonMichele Schiavon
Michele Schiavon
ABAnanda Basu
Ananda Basu
CCClaudio Cobelli
Claudio Cobelli
RBRita Basu
Rita Basu
Chiara Dalla ManChiara Dalla Man
Chiara Dalla Man
Exercise effects (EE) on whole body glucose rate of disappearance (Rd) occur through insulin-independent (IIRd) and insulin-dependent (IDRd) mechanisms. Quantifying these processes in vivo would allow a better understanding of the physiology of glucose regulation. This is of particular importance in individuals with type 1 diabetes (T1D) since such a knowledge may help to improve glucose management. However, such a model is still lacking. Here, we analyzed data from six T1D and six nondiabetic (ND) subjects undergoing a labeled glucose clamp study during, before, and after a 60-min exercise session at 65% V̇o2max on three randomized visits: euglycemia-low insulin, euglycemia-high insulin, and hyperglycemia-low insulin. We tested a set of models, all sharing a single-compartment description of glucose kinetics, but differing in how exercise is assumed to modulate glucose disposal. Model selection was based on parsimony criteria. The best model assumed an exercise-induced immediate effect on IIRd and a delayed effect on IDRd. It predicted that exercise increases IIRd, compared with rest, by 66%–82% and 67%–97% in T1D and ND, respectively, not significantly different between the two groups. Conversely, the exercise effect on IDRd ranged between 81% and 155% in T1D and it was significantly higher than ND, which ranged between 10% and 40%. The exaggerated effect observed in IDRd can explain the higher hypoglycemia risk related to individuals with T1D. This novel exercise model could help in informing safe and effective glucose management during and after exercise in individuals with T1D. NEW & NOTEWORTHY Here, we present a new mathematical model describing the effect of moderate physical activity on insulin-mediated and noninsulin-mediated glucose disposal in subjects with and without diabetes. We believe that this represents a step-forward in the knowledge of type 1 diabetes pathophysiology, and an useful tool to design safe and effective insulin-therapies.

6 February 2019 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Closed access
Roberto VisentinRoberto Visentin
Roberto Visentin
Michele SchiavonMichele Schiavon
Michele Schiavon
CGClemens Giegerich
Clemens Giegerich
TKThomas Klabunde
Thomas Klabunde
Chiara Dalla ManChiara Dalla Man
Chiara Dalla Man
CCClaudio Cobelli
Claudio Cobelli
Glargine 100 U/mL (Gla-100) and 300 U/mL (Gla-300) are long-acting insulin analogs providing basal insulin supply in multiple daily injection (MDI) therapy of type 1 diabetes (T1D). Both insulins require extensive testing to arrive at the optimal dosing regimen, e.g., timing and amount. Here we aim at a simulation tool for evaluating benefits/risks of different dosing schemes and up-titration rules for both Gla-100 and Gla-300 before clinical testing. A new pharmacokinetic (PK) model of both Gla-100 and Gla-300 was incorporated into the FDA-accepted University of Virginia/Padova T1D simulator: Specifically, a joint parameter distribution, built from PK parameter estimates, was used to generate individual PK parametrizations for each in silico subject. A virtual trial comparing Gla-100 vs. Gla-300 was performed and assessed against a clinical study to validate the glargine simulator. Like in vivo, in silico both insulins performed similarly with respect to glucose control: percent time of glucose between [80-140] mg/dL with Gla-100 vs. Gla-300 (primary endpoint) were 41.5 ± 1.1% vs. 39.0 ± 1.2% (P = 0.11) in silico, 31.0 ± 1.6% vs. 31.8 ± 1.5% (P = 0.73) in vivo. The glargine simulator reproduced the main findings of the clinical trial, proving its validity for testing MDI therapies. In silico testing of MDI therapies can help designing clinical trials. Due to the more standardized settings in silico (e.g., standardized meals and strict adherence to titration rule), any potential treatment effect is reaching statistical significance in simulation vs. clinical trial.

21 September 2023 in The Journal of Physiology
Verified
Journal Article
Closed access
JKJill A. Kanaley
Jill A. Kanaley
JPJ. W. Porter
J. W. Porter
NWN. C. Winn
N. C. Winn
GLG. Lastra
G. Lastra
ACA. Chockalingam
A. Chockalingam
EPE. J. Parks
E. J. Parks

17 January 2023 in Diabetologia
Verified
Journal Article
Open access
PDF file
ATAfroditi Tripyla
Afroditi Tripyla
DHDavid Herzig
David Herzig
GRGemma Reverter-Branchat
Gemma Reverter-Branchat
JPJacopo Pavan
Jacopo Pavan
Michele SchiavonMichele Schiavon
Michele Schiavon
Lia BallyLia Bally
Lia Bally
Aims/hypothesis: Post-bariatric hypoglycaemia is an increasingly recognised complication of bariatric surgery, manifesting particularly after Roux-en-Y gastric bypass. While hyperinsulinaemia is an established pathophysiological feature, the role of counter-regulation remains unclear. We aimed to assess counter-regulatory hormones and glucose fluxes during insulin-induced postprandial hypoglycaemia in patients with post-bariatric hypoglycaemia after Roux-en-Y gastric bypass vs surgical and non-surgical control individuals. Methods: In this case–control study, 32 adults belonging to four groups with comparable age, sex and BMI (patients with post-bariatric hypoglycaemia, Roux-en-Y gastric bypass, sleeve gastrectomy and non-surgical control individuals) underwent a postprandial hypoglycaemic clamp in our clinical research unit to reach the glycaemic target of 2.5 mmol/l 150–170 min after ingesting 15 g of glucose. Glucose fluxes were assessed during the postprandial and hypoglycaemic period using a dual-tracer approach. The primary outcome was the incremental AUC of glucagon during hypoglycaemia. Catecholamines, cortisol, growth hormone, pancreatic polypeptide and endogenous glucose production were also analysed during hypoglycaemia. Results: The rate of glucose appearance after oral administration, as well as the rates of total glucose appearance and glucose disappearance, were higher in both Roux-en-Y gastric bypass groups vs the non-surgical control group in the early postprandial period (all p<0.05). During hypoglycaemia, glucagon exposure was significantly lower in all surgical groups vs the non-surgical control group (all p<0.01). Pancreatic polypeptide levels were significantly lower in patients with post-bariatric hypoglycaemia vs the non-surgical control group (median [IQR]: 24.7 [10.9, 38.7] pmol/l vs 238.7 [186.3, 288.9] pmol/l) (p=0.005). Other hormonal responses to hypoglycaemia and endogenous glucose production did not significantly differ between the groups. Conclusions/interpretation: The glucagon response to insulin-induced postprandial hypoglycaemia is lower in post-bariatric surgery individuals compared with non-surgical control individuals, irrespective of the surgical modality. No significant differences were found between patients with post-bariatric hypoglycaemia and surgical control individuals, suggesting that impaired counter-regulation is not a root cause of post-bariatric hypoglycaemia. Trial registration: ClinicalTrials.gov NCT04334161 Graphical